Following the success of the first Volume: Non-coding RNAs in Gastrointestinal and Gynecological Cancers: New Insights into the Mechanisms of Cancer Therapeutic Resistance this Volume II research topic is aimed at providing researchers with an exclusive platform to publish their latest discoveries in this field.

Gastrointestinal cancers (including colon, stomach, liver, and pancreatic cancer) and gynecological cancers (including ovarian, endometrial, and cervical cancer) are common types of solid malignancies worldwide. The cancer cell resistance to anti-cancer treatments (chemotherapy, radiotherapy, and targeted therapies) can occur due to many different mechanisms, including specific genetic and epigenetic changes in the cancer cell and tumor microenvironment that help cancer cells to reside. To develop new strategies to overcome intrinsic and acquired resistance that limit the effectiveness of anti-cancer therapies, clarification of the underlying molecular mechanisms affecting therapeutic responses in gastrointestinal and gynecological cancers is urgently needed.
Non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), PIWI-interacting RNAs (piRNAs), and circular RNAs (circRNAs), make up most of the human transcriptome and have been hot spots in recent years. Accumulating evidence indicates that miRNAs, lncRNAs, and circRNAs play crucial roles in tumorigenesis, tumor development, metastasis, and sensitivity to radiation, chemotherapy, and targeted therapies.
The aim of this Volume II Research Topic is to provide updated findings on, computational and experimental insights into the therapeutic resistance mechanisms regulated by non-coding RNAs in human cancers (especially gastrointestinal and gynecological cancers).

We welcome original research articles and reviews that explore, but are not limited to, the following list of themes:
• New non-coding RNAs that predict anti-cancer medication response or resistance.
• Novel epigenetic pathways governing epithelial-to-mesenchymal transition (EMT), cancer stemness, angiogenesis, proliferation, inflammation, and immune evasion.
• Interplay between miRNAs, lncRNAs, and circRNAs as a molecular basis for cancer therapy resistance.
• The role and underlying mechanism of piRNAs in cancer development and chemoresistance.
• Creating novel cancer therapeutics based on non-coding RNAs.
• New experimental approaches for investigating cancer epigenetics and therapeutic resistance.

Submit your idea

Impact

Frontiers in Cell and Developmental Biology

Participating Journals

Impact